Article Text
PDFCommentary
General medicine
CETP inhibition improves the lipid profile but has no effect on clinical cardiovascular outcomes in high-risk patients
Statistics from Altmetric.com
Footnotes
Competing interests RR received funding for a steering committee on the use of PCSK9 inhibitors in familial hypercholesterolaemia for Eli Lilly. This development program was terminated earlier this year.
Provenance and peer review Commissioned; internally peer reviewed.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.